🇺🇸 FDA
Patent

US 10450585

Delivery methods and compositions for nuclease-mediated genome engineering

granted A61KA61K2239/29A61K38/37

Quick answer

US patent 10450585 (Delivery methods and compositions for nuclease-mediated genome engineering) held by Sangamo Therapeutics, Inc. expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2239/29, A61K38/37, A61K38/4846, A61K40/11